McKesson Reports Strong Q3 Earnings, Raises Guidance, and Advances Medical-Surgical Separation Plans

McKesson reported strong Q3 earnings with double-digit growth in revenue and adjusted EPS. The company expanded its oncology, biopharma services, and North American pharmaceutical distribution operations. Management raised full-year earnings guidance and highlighted progress toward separating the medical-surgical business. The separation plan includes a potential IPO of the medical-surgical unit. Key to watch are how the separation develops, the integration of recent acquisitions, and the impact of technology and services investments on margins.